London phone chat trials
Immu Pharma has the potential of expanding the P140 peptide platform into other auto immune conditions such as: Rheumatoid Arthritis, Crohn’s Disease, and Asthma.Very few AIM-listed drug development companies have late-stage clinical assets of similar calibre.I think clinical trials are the best possible way to approach this issue.Lots of things in “research integrity” are hard to capture in hard logical rules, so you end up with waffly “concordats” and rules that are applied inconsistently.Sorry not to be in regular blogging mode at the moment.
While companies superficially have commitments to register and report clinical trials, in reality, there are often huge gaps in their policies, with many failing to include past trials (trials on the medicines we use today) and trials on off-label uses or unlicensed medicines, which are both important.
Immu Pharma PLC is a pharmaceutical development company focusing on developing novel medicines in specialist markets with serious unmet need.
Lupuzor™ is the company’s most advanced drug in development and is a treatment for lupus, a life threatening autoimmune disease and has now completed dosing Lupus patients in its Phase III pivotal trial.
With clinical trials you can make clear rules, you can measure compliance, and you can enforce compliance.
There is lots of chat about this in the video below from with me, Simon Read the rest of this entry » Regular readers will be familiar with this ongoing battle.